About this trial
This study will test whether astaxanthin, a naturally occurring antioxidant supplement, can improve lung function, reduce airway inflammation, and improve asthma control in adults with mild-to-moderate asthma. Participants will receive astaxanthin and placebo in random order in a double-blind crossover design. Each treatment period lasts 4 weeks and is separated by a 3-week washout period. The study also measures indoor and personal air pollution exposure to examine whether pollution influences asthma symptoms, airway responsiveness, and response to treatment. Exploratory thoracic bioelectrical impedance spectroscopy will be assessed alongside standard respiratory tests.
Eligibility criteria
Qualifiers
Adults 18+ y
A physician diagnosed asthma condition consistent with BTS/NICE/SIGN (2024)
Asthma managed at GINA (2024) step 1-3 therapy level, with stable maintenance treatment for ≥4 weeks prior to enrolment
No asthma exacerbation requiring systemic corticosteroids within the preceding 6-8 weeks
Disqualifiers
Current smokers or vapers which is associated with chronic airway remodelling, reduce hyperresponsiveness to bronchodilators, and increased neutrophilic inflammation, which can obscure the true effects of asthma-target interventions
Respiratory tract infection within the preceding 4 weeks
Pregnant or lactating individuals
Presence of significant co-morbidities, including CVD or autoimmune or systemic inflammatory diseases
Trial design
Treatments tested in this trial
- Astaxanthin Oral Capsule
- Matched Placebo (Capsules)
Treatment groups
Sponsors and collaborators
Middlesex University
Lead sponsor
AstaReal
Collaborator
BodyStat Ltd.
Collaborator
British Pest Control Association
Collaborator